Tarsus Pharmaceuticals, Inc. (TARS)
Health Care ยท Biological Products, (No Diagnostic Substances)
Tarsus Pharmaceuticals, Inc. (TARS) is listed on Nasdaq, where its shares have traded since October 16, 2020. SentiSense covers Tarsus Pharmaceuticals, Inc. in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances). Bobak Azamian is its chief executive officer. The company reports 370 employees, and its corporate website is www.tarsusrx.com.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Latest reported results
Tarsus Pharmaceuticals Inc. reported revenue of $194.6 million for Q3 FY2026, up 63.9% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 249 institutions reported holding TARS, with 47.3 million shares worth $3.0 billion in aggregate. The largest reported holders were BlackRock, Deep Track Capital and Rtw Investments. Of the 5 largest reported holders, all 5 added shares during the quarter.
More on TARS
- TARS sentiment: whether news and social coverage of Tarsus Pharmaceuticals, Inc. leans bullish or bearish, and the stories driving it.
- TARS ownership: all 249 reporting institutions, plus insider and congressional trades.
- TARS financials: revenue, net income, operating margin and free cash flow through Q3 FY2026.
SentiSense also tracks daily options readings for Tarsus Pharmaceuticals, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Tarsus Pharmaceuticals, Inc. do?
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care.
What sector is TARS in?
SentiSense classifies Tarsus Pharmaceuticals, Inc. in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances).
Where does TARS stock trade?
Tarsus Pharmaceuticals, Inc. (TARS) is listed on Nasdaq, where its shares have traded since October 16, 2020.
Who is the CEO of Tarsus Pharmaceuticals, Inc.?
Bobak Azamian is the chief executive officer of Tarsus Pharmaceuticals, Inc..